Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daytrana dermal reactions in pediatric ADHD
NCT00434213Phase 4Completed
- Sponsor
- Noven Therapeutics, LLC
- Start
- Jan 2007
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate transdermal system in attention deficit hyperactivity disorder (ADHD), sponsored by Noven Therapeutics, LLC. Primary endpoint: Dermal Reactions at 7 weeks. Started Jan 2007; status: completed.
02
Drugs
methylphenidate transdermal system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00434213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434213.